COMPARISON
Octreotide vs Sermorelin
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Octreotide is authorised or registered in 10 and Sermorelin in 0 of the 10 registers read. Octreotide: highest phase Phase 4 (after approval). Sermorelin: No trial states a phase. 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Octreotide | Sermorelin | |
|---|---|---|
| Registered trials differs | 344 clinicaltrials.gov · 2026-10-03 | 27 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z | Not checked no record of "fdaLabel" for sermorelin |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2025-06-30 ema · 2026-10-03 | Not checked no record of "authorisedOn" for sermorelin |
| EU withdrawn on differs | 2022-12-02 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for sermorelin |
| ATC code differs | H01CB02 ema · 2026-10-03 | Not checked no record of "atcCode" for sermorelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Octreotide | placebo | Sermorelin | placebo |
|---|---|---|---|---|
| Diarrhoea | 46.2% | 31.7% | - | - |
| Oedema peripheral | 34.9% | 19.6% | - | - |
| Asthenia | 33.3% | 20.9% | - | - |
| Nausea | 30.8% | 21.2% | - | - |
| Fatigue | 29.8% | 27.7% | - | - |
| Rash | 28.8% | 14.1% | - | - |
| Decreased appetite | 28.5% | 15.2% | - | - |
| Hypertension | 26.5% | 19.4% | - | - |
| Dyspnoea | 25.9% | 9.1% | - | - |
| Anaemia | 24.3% | 9.1% | - | - |
Trial register Octreotide: 5 placebo-controlled trials; Sermorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Octreotide side effects · Sermorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Octreotide | Sermorelin | Register |
|---|---|---|---|
| United States | FDA-approved | Not on the register | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Not on the register | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Not on the register | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT03031535 | Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers COMPLETED · updated 2017-05-12 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.